In silico cancer research towards 3R
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Improving our understanding of cancer and other complex diseases requires integrating diverse data sets and algorithms. Intertwining in vivo and in vitro data and in silico models are paramount to overcome intrinsic difficulties given by data complexity. Importantly, this approach also helps to uncover underlying molecular mechanisms. Over the years, research has introduced multiple biochemical and computational methods to study the disease, many of which require animal experiments. However, modeling systems and the comparison of cellular processes in both eukaryotes and prokaryotes help to understand specific aspects of uncontrolled cell growth, eventually leading to improved planning of future experiments. According to the principles for humane techniques milestones in alternative animal testing involve in vitro methods such as cell-based models and microfluidic chips, as well as clinical tests of microdosing and imaging. Up-to-date, the range of alternative methods has expanded towards computational approaches, based on the use of information from past in vitro and in vivo experiments. In fact, in silico techniques are often underrated but can be vital to understanding fundamental processes in cancer. They can rival accuracy of biological assays, and they can provide essential focus and direction to reduce experimental cost. MAIN BODY: We give an overview on in vivo, in vitro and in silico methods used in cancer research. Common models as cell-lines, xenografts, or genetically modified rodents reflect relevant pathological processes to a different degree, but can not replicate the full spectrum of human disease. There is an increasing importance of computational biology, advancing from the task of assisting biological analysis with network biology approaches as the basis for understanding a cell's functional organization up to model building for predictive systems. CONCLUSION: Underlining and extending the in silico approach with respect to the 3Rs for replacement, reduction and refinement will lead cancer research towards efficient and effective precision medicine. Therefore, we suggest refined translational models and testing methods based on integrative analyses and the incorporation of computational biology within cancer research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“…available through collaborative projects such as the International Cancer Genome Consortium or The Cancer Genome Atlas (TCGA) [62] and others [128], together with functional network analysis using de novo pathway learning methods or databases on known pathways such as Gene Ontology [129],…”
MethodThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
A pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371 · cited 1×
“This database provides cancer protein signatures to be analysed for potential biomarkers [111, 112].”
BackgroundComputational systems biology.
Kitano, H. (2002) · Nature · doi:10.1038/nature01254 · Cited by 2,209
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090
Expansion of the Gene Ontology knowledgebase and resources
The Gene Ontology Consortium (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1108 · Cited by 1,850 · cited 1×
“…Genome Consortium or The Cancer Genome Atlas (TCGA) [62] and others [128], together with functional network analysis using de novo pathway learning methods or databases on known pathways such as Gene Ontology [129], Reactome [130] or the Kyoto Encyclopedia of Genes and Genomes (KEGG) [131–134].”
Method
Cited by
AI in Medical Imaging Informatics: Current Challenges and Future Directions
Panayides, A. S., Amini, A., Filipovic, N. D., Sharma, A., Tsaftaris, S. A., Young, A., Foran, D., Do, N., Golemati, S., Kurc, T., et al. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2991043 · Cited by 713
“They facilitate model development in precision medicine under the 3R principles of in vivo experimentation related to replacement, reduction and refinement [218] of experimentation on life samples.”
Holzinger, A., Malle, B., Saranti, A., & Pfeifer, B. (2021) · Information Fusion · doi:10.1016/j.inffus.2021.01.008 · Cited by 352
Self-citationViceconti, M., Pappalardo, F., Rodriguez, B., Horner, M., Bischoff, J., & Musuamba Tshinanu, F. (2021) · Methods · doi:10.1016/j.ymeth.2020.01.011 · Cited by 361
“In addition, modelling and simulation is being used to reduce, refine and replace animal experimentation [9,10], and even to replace bench tests [11,12].”
MethodThree-dimensional in vitro culture models in oncology research
Jubelin, C., Muñoz-Garcia, J., Griscom, L., Cochonneau, D., Ollivier, E., Heymann, M.-F., Vallette, F. M., Oliver, L., & Heymann, D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00887-3 · Cited by 264
Animal-derived products in science and current alternatives
Duarte, A. C., Costa, E. C., Filipe, H. A. L., Saraiva, S. M., Jacinto, T., Miguel, S. P., Ribeiro, M. P., & Coutinho, P. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213428 · Cited by 117
Metadata
- Authors
- Jean-Quartier, C., Jeanquartier, F., Jurisica, I., & Holzinger, A.
- Venue
- BMC Cancer
- Published
- 2018-04-12
- Volume
- 18
- Issue
- 1
- Pages
- 408-408
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2807132016
- Cited by
- 126
- References
- 21
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In silico cancer research towards 3R. https://app.cochat.ai/papers/10.1186/s12885-018-4302-0
- The paper
- Jean-Quartier, C., Jeanquartier, F., Jurisica, I., & Holzinger, A. (2018). In silico cancer research towards 3R. BMC Cancer. https://doi.org/10.1186/s12885-018-4302-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.